StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Coherus Oncology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Coherus Oncology's price to sales ratio was 1.8× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 0.5× to 6.8×, with a median of 2.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.8×−2.7
2025Dec 31, 20254.4×+3.0
2024Dec 31, 20241.4×−0.3
2023Dec 29, 20231.7×−0.9
2022Dec 30, 20222.6×−0.8
2021Dec 31, 20213.4×+0.5
2020Dec 31, 20202.9×−2.9
2019Dec 31, 20195.7×−459.6
2018Apr 30, 2018465.3×+283.4
2017Dec 29, 2017181.9×+175.9
2016Dec 30, 20166.0×−23.0
2015Dec 31, 201529.0×+26.1
2014Dec 31, 20142.9×–

More Coherus Oncology figures

See a number that looks wrong?